In addition, increasing pediatric data is emerging for BRAF and MEK inhibitors in the treatment of surgically inaccessible gliomas that express BRAF V600E mutations, with an acceptable side effect profile in this age group [1, 3, 4, 16, 18, 29]. This evidence concerns the gene MAP2K7 and glioma.